| Product Code: ETC9215913 | Publication Date: Sep 2024 | Updated Date: Feb 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Serbia`s import trend for patient-derived xenograft (PDX) models market showed significant growth, with a growth rate of 250.98% from 2023 to 2024 and a compound annual growth rate (CAGR) of 41.9% for the period 2020-2024. This surge may be attributed to increasing demand for advanced biomedical research tools in the region.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Serbia Patient Derived Xenograft (PDX) Models Market Overview |
3.1 Serbia Country Macro Economic Indicators |
3.2 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, 2022 & 2032F |
3.3 Serbia Patient Derived Xenograft (PDX) Models Market - Industry Life Cycle |
3.4 Serbia Patient Derived Xenograft (PDX) Models Market - Porter's Five Forces |
3.5 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Type, 2022 & 2032F |
3.6 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Tumor Type, 2022 & 2032F |
3.7 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Application, 2022 & 2032F |
3.8 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Technique, 2022 & 2032F |
3.9 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 Serbia Patient Derived Xenograft (PDX) Models Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for personalized medicine and targeted therapies |
4.2.2 Growing prevalence of cancer and the need for more accurate preclinical models |
4.2.3 Rising investments in research and development in the healthcare sector |
4.3 Market Restraints |
4.3.1 High cost associated with the development and maintenance of patient-derived xenograft (PDX) models |
4.3.2 Ethical concerns related to the use of animal models in research |
4.3.3 Limited availability of skilled personnel for PDX model development and analysis |
5 Serbia Patient Derived Xenograft (PDX) Models Market Trends |
6 Serbia Patient Derived Xenograft (PDX) Models Market, By Types |
6.1 Serbia Patient Derived Xenograft (PDX) Models Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Type, 2022-2032F |
6.1.3 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Mice Models, 2022-2032F |
6.1.4 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Rat Models, 2022-2032F |
6.2 Serbia Patient Derived Xenograft (PDX) Models Market, By Tumor Type |
6.2.1 Overview and Analysis |
6.2.2 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Gastrointestinal Tumor Models, 2022-2032F |
6.2.3 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Lung Tumor Models, 2022-2032F |
6.2.4 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Haematological Tumor Models, 2022-2032F |
6.3 Serbia Patient Derived Xenograft (PDX) Models Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Preclinical Drug Development, 2022-2032F |
6.3.3 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Precision Medicine, 2022-2032F |
6.3.4 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Co-Clinical Trials, 2022-2032F |
6.3.5 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Basic Cancer Research, 2022-2032F |
6.3.6 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Biomarker Analysis, 2022-2032F |
6.3.7 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Oncology Research, 2022-2032F |
6.4 Serbia Patient Derived Xenograft (PDX) Models Market, By Technique |
6.4.1 Overview and Analysis |
6.4.2 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Heterotopic Implantation, 2022-2032F |
6.4.3 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Orthotropic Implantation, 2022-2032F |
6.5 Serbia Patient Derived Xenograft (PDX) Models Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Academic and Research Organizations, 2022-2032F |
6.5.3 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Contract Research Organizations, 2022-2032F |
6.5.4 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Pharmaceutical and Biotechnological Companies, 2022-2032F |
6.5.5 Serbia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Others, 2022-2032F |
7 Serbia Patient Derived Xenograft (PDX) Models Market Import-Export Trade Statistics |
7.1 Serbia Patient Derived Xenograft (PDX) Models Market Export to Major Countries |
7.2 Serbia Patient Derived Xenograft (PDX) Models Market Imports from Major Countries |
8 Serbia Patient Derived Xenograft (PDX) Models Market Key Performance Indicators |
8.1 Average time taken to develop a new PDX model |
8.2 Number of collaborative partnerships with research institutions and pharmaceutical companies |
8.3 Percentage of successful translation of results from PDX models to clinical trials |
9 Serbia Patient Derived Xenograft (PDX) Models Market - Opportunity Assessment |
9.1 Serbia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Type, 2022 & 2032F |
9.2 Serbia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Tumor Type, 2022 & 2032F |
9.3 Serbia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Application, 2022 & 2032F |
9.4 Serbia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Technique, 2022 & 2032F |
9.5 Serbia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By End User, 2022 & 2032F |
10 Serbia Patient Derived Xenograft (PDX) Models Market - Competitive Landscape |
10.1 Serbia Patient Derived Xenograft (PDX) Models Market Revenue Share, By Companies, 2025 |
10.2 Serbia Patient Derived Xenograft (PDX) Models Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here